Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | RARA | P10276 | 4/20 | 0.49 |
| ▸ | RARB | P10826 | 4/20 | 0.49 |
| ▸ | RARG | P13631 | 4/20 | 0.49 |
| ▸ | RXRA | P19793 | 4/20 | 0.49 |
| ▸ | CNR1 | P21554 | 7/20 | 0.48 |
| ▸ | CNR2 | P34972 | 7/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12594103 | 0.89 | ALDH1A1 (0.55) | ALDH1A1RARARARBRARGRXRA | |
| SCHEMBL1107579 | 0.83 | CA9 (0.53) | ALDH1A1CNR1CNR2EPHX2PTGS2 | |
| SCHEMBL4083414 | 0.83 | ALDH1A1 (1.00) | ALDH1A1CNR1CNR2 | |
| SCHEMBL28287989 | 0.82 | ALDH1A1 (0.76) | ALDH1A1CNR1CNR2 | |
| SCHEMBL9979626 | 0.78 | PTGS2 (0.62) | CNR1CNR2EPHX2PTGS2ALOX5 | |
| SCHEMBL1132436 | 0.77 | EPHX2 (0.43) | ALDH1A1RARARARBRARGRXRA | |
| SCHEMBL9979750 | 0.76 | EPHX2 (0.52) | ALDH1A1RARARARBRARGRXRA | |
| SCHEMBL10147881 | 0.75 | SMN1; SMN2 (0.71) | PTGS2ALOX5 | |
| SCHEMBL9207362 | 0.75 | RPA1 (0.62) | PTGS2ALOX5 | |
| SCHEMBL9209000 | 0.75 | SMN1; SMN2 (0.71) | PTGS2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | ALDH1A1 4620/4885RARA 2614/4885RARB 2753/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | ALDH1A1 4539/4885RARA 2986/4885RARB 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.